Racial and sociodemographic disparities in the use of targeted therapies in advanced ovarian cancer patients with Medicare.

ABSTRACT:

Objective

To describe sociodemographic and racial disparities in receipt of poly ADP-ribose polymerase inhibitors (PARPi) and bevacizumab among insured patients with ovarian cancer.

Methods

This retrospective study used the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to identify patients with advanced stage, high grade serous ovarian cancer diagnosed between 2010 and 2019. The primary outcome of interest was receipt of PARPi or bevacizumab at any time after diagnosis. χ² tests were used to compare categorical variables. Factors independently associated with the receipt of PARPi and/or bevacizumab were identified using a multivariable logistic regression.

Results

The cohort included 6242 patients; 276 (4.4%) received PARPi, 2142 (34.

SUBMITTER: Knisely A 

PROVIDER: S-EPMC11534538 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature